Daniel D Gretler Selected Research

elinogrel

6/2012

A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial.

12/2009

Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rapid ReversAl of platelet thromboSis with intravenous Elinogrel before PCI to optimize reperfusion in acute Myocardial Infarction (ERASE MI) pilot trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Daniel D Gretler Research Topics

Disease

5	Hemorrhage 05/2013 - 03/2004
2	Sickle Cell Anemia (Hemoglobin S Disease) 01/2019 - 01/2019
2	Myocardial Infarction 06/2012 - 12/2009
2	Acute Coronary Syndrome 03/2004 - 10/2003
1	Hypoxia (Hypoxemia) 01/2019
1	Hemolytic Anemia 01/2019
1	Hemolysis 01/2019
1	Anemia 01/2019
1	Autoimmune Diseases (Autoimmune Disease) 01/2017
1	Experimental Arthritis 01/2017
1	Neoplasms (Cancer) 01/2017
1	Atrial Fibrillation 05/2013
1	Ischemic Stroke 05/2013
1	Stroke (Strokes) 05/2013
1	Heart Block 06/2012
1	Liver Failure 06/2012
1	Hypotension (Low Blood Pressure) 06/2012
1	Dyspnea (Shortness of Breath) 06/2012
1	Bradycardia 06/2012
1	Body Weight (Weight, Body) 12/2011
1	Obesity 12/2011
1	Thrombosis (Thrombus) 12/2009
1	ST Elevation Myocardial Infarction 12/2009
1	Venous Thromboembolism 01/2009

Drug/Important Bio-Agent (IBA)

3	Eptifibatide (Integrilin)FDA Link 12/2011 - 10/2003
2	voxelotorIBA 01/2019 - 01/2019
2	Oxygen (Dioxygen)IBA 01/2019 - 01/2019
2	Pharmaceutical PreparationsIBA 01/2019 - 03/2004
2	betrixabanIBA 05/2013 - 01/2009
2	Clopidogrel (Plavix)FDA Link 06/2012 - 07/2010
2	elinogrelIBA 06/2012 - 12/2009
1	Sickle HemoglobinIBA 01/2019
1	Hemoglobins (Hemoglobin)IBA 01/2019
1	4- (3- (2H- 1,2,3- triazol- 2- yl)phenylamino)- 2- (2- aminocyclohexylamino)pyrimidine- 5- carboxamideIBA 01/2017
1	Syk KinaseIBA 01/2017
1	Warfarin (Coumadin)FDA LinkGeneric 05/2013
1	Aspartic Acid (Aspartate)FDA Link 06/2012
1	Alanine (L-Alanine)FDA Link 06/2012
1	TransferasesIBA 06/2012
1	EnzymesIBA 06/2012
1	Transaminases (Aminotransferases)IBA 06/2012
1	Purinergic P2Y Receptor AntagonistsIBA 12/2009
1	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 12/2009
1	Purinergic P2 Receptors (ADP Receptor)IBA 12/2009
1	Factor Xa (Coagulation Factor Xa)IBA 01/2009
1	Platelet Membrane Glycoprotein IIbIBA 10/2003
1	AntithrombinsIBA 10/2003
1	Glycoproteins (Glycoprotein)IBA 10/2003
1	Heparin (Liquaemin)FDA LinkGeneric 10/2003

Therapy/Procedure

4	Therapeutics 01/2019 - 10/2003
4	Percutaneous Coronary Intervention 06/2012 - 10/2003